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The role of the atrial natriuretic factor and of the 
main counteracting sodium-retaining principle, the 
renin-aldosterone system, in acute volume regulation of 
cirrhosis of the liver has been investigated. Central 
volume stimulation was achieved in 21 patients with 
cirrhosis, 11 without and 10 with ascites, and 25 healthy 
controls by 1-hr head-out water immersion. Immersion 
prompted a highly significant (p c 0.001) increase of 
atrial natriuretic factor plasma concentrations in cir- 
rhotic patients without ascites from 8.5 f 1.3 fmoles per 
ml to 16.5 2 2.6 fmoles per ml, comparable to the stim- 
ulation in control subjects (6.0 2 0.6 fmoles per ml to 
13.6 f 2.6 fmoles per ml). In cirrhotic patients with 
ascites, atrial natriuretic factor increase (from 7.7 f 1.3 
fmoles per ml to 11.4 2 2.3 fmoles per ml) was blunted 
(p < 0.05). Plasma renin activity and plasma aldosterone 
concentration were elevated in cirrhotic patients, espe- 
cially in the presence of ascites. Following immersion, 
plasma renin activity and plasma aldosterone concen- 
tration were reduced similarly in all groups. Water im- 
mersion induced a more pronounced natriuresis and 
diuresis in control subjects than in cirrhotic patients. 
Neither atrial natriuretic factor nor plasma renin activ- 
ity nor plasma aldosterone concentration alone corre- 
lated to sodium excretion. However, atrial natriuretic 
factor to plasma aldosterone concentration ratios were 
closely correlated to basal and stimulated natriuresis in 
cirrhotic patients, particularly in those with ascites. 
These data suggest that atrial natriuretic factor and the 
renin-aldosterone system influence volume regulation 
in patients with cirrhosis. 
Current concepts of the pathophysiology of renal so- 
dium retention and ascites formation in patients with 
cirrhosis of the liver have progressively become more 
complex (1). Stimulation of the renin-aldosterone system 
is still considered important for the impaired volume 
regulation of cirrhosis ( a ) ,  but there is increasing evi- 
dence for the involvement of other humoral factors ( 3 ) .  
Received October 27, 1987; accepted August 2 2 ,  1988. 
Parts of this study were presented at the :38th Annual Meeting t i t  
the American Association for the Study of Liver Diseases. Chicagci. 
1987, and at  the Second World Congress (in Biologically Active Pltrinl 
Peptides, New York, 1987. 
Address reprint requests t.o: Alexander I,. Gerbes. M.D.. Mediziii- 
ische Klinik 11, Klinikum Grosshadern. 1 Triiversity of Munich. Munich, 
Federal Republic of Germany. 
For many years, a deficiency of’ a putative natriuretic 
hormone in cirrhosis has been postulated (4, 5), but due 
to difficulties with precise characterization and quanti- 
fication, the role of this hormone has not been satisfac- 
t,orily elucidated (6). Since the discovery of the well- 
defined atrial natriuretic fact.or [ANF; for review, see 
Refs. (7-12)]? the role of this hormonal peptide in cir- 
rhosis has been of major interest. It has been demon- 
strated that plasma levels of ANF, determined by radio- 
immunoassay, were not lower in cirrhosis than in healthy 
subjects (13). Although several laboratories have con- 
firmed that there is no deficiency of plasma ANF in 
cirrhosis [for overview, see Ref. ( lo ) ] ,  reported plasma 
levels vary in a wide range and presently the importance 
of ANF in volume regulation in healthy man as well as 
in patients with cirrhosis is ill defined. 
Several observations suggest a counteraction of ANF 
with the sodium-retaining renin-aldosterone system (14- 
1’7): ANF inhibits the synthesis of aldosterone and blocks 
the release of renin as well as of aldosterone. Upon ANF 
infusion, a decline of plasma renin activity (PRA) and 
of plasma aldosterone concentration (PAC) were ob- 
served (18). It  has been speculated that the sodium 
retention and activation of the renin-aldosterone system 
in cirrhosis may result from derangements of ANF re- 
lease or action (19). Therefore, in the present study the 
relationship of both hormonal systems in the volume 
regulation of cirrhosis has been investigated. 
The characterization of the reactivity to stimulation 
of these hormonal systems may allow pathophysiological 
insights not provided by the determination of basal 
plasma levels alone. As a tool for acute volume stimula- 
tion. head-out, water immersion (WI) increases central 
venous and atrial volume by shift.ing blood from the 
peripheral vessels to the intrathoracic venous bed (20), 
obviating the necessity of infusing plasma expanders that, 
might alter plasma composition (21). 
Using this approach, the role of ANF and the counter- 
acting renin-aldosterone system in acute volume regula- 
tion of pat,ients with cirrhosis have been examined. 
SUBJECTS AND METHODS 
rwenty-five healthy subjects, age 19 to 65 (mean: 35 f 3) 
wars and 21 patients with cirrhosis (12 alcoholic, six hepatitic, 
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three cryptogenic) age 42 to 75 (mean: 59 -C 2) years were 
investigated after informed consent had been obtained. The 
protocol was approved by the Ethical Committee of the Faculty 
of Medicine, University of Munich. The subjects showed no 
evidence of cardiovascular, renal, pulmonary or endocrine dis- 
eases. The diagnosis of cirrhosis was established by biopsy, 
clinical and laboratory data. In 11 patients, no ascites could be 
detected by abdominal ultrasound. In this group, nine patients 
were ranked Grade A and two Grade B according to a modified 
Child-Pugh classification (22, 23). In 10 patients, presence of 
ascites was confirmed by clinical investigation and abdominal 
ultrasound; six of them were graded B, and four were graded C 
according to Child-Pugh. They all had a history of longstand- 
ing, stable ascites. Further clinical and laboratory data of 
patients are reported in Table 1. Cirrhotic patients had been 
withheld diuretic treatment for 1 week prior to the study. All 
subjects were prohibited alcohol, tobacco, tea and coffee the 
day before and during the experiment and were on a hospital 
diet containing approximately 150 mEq sodium per day. 
In the morning, after complete emptying of the bladder, an 
intravenous catheter was placed into a forearm vein. Subjects 
were given 400 ml of water orally and assumed a seated position 
next to the immersion tank. After 1 hr, the subjects were 
immersed to their neck, maintaining the same seated position, 
into thermoneutral water (34.5 & 0.2%) for 1 hr. This was 
followed by a 1-hr period of sitting outside the tank. Through- 
out the investigation, 200 ml per hr of water were given orally 
to ensure adequate urine flow. All the urine voided by sponta- 
neous emptying of the bladder as well as plasma samples were 
collected before (baseline), after 1-hr WI (immersion) and 1 hr 
subsequent to the end of WI (recovery). 
Urine was analyzed for sodium, potassium (flame photome- 
try) and creatinine (Jaffe reaction). PRA was measured as 
described before (3). PAC was determined by use of a commer- 
cial kit (Diagnostic Products, Los Angeles, CA). ANF was 
measured in XAD-extracted plasma samples by radioimmuno- 
assay, as described in detail earlier (24). Briefly, the antibody 
is mid-molecule- and C-terminal directed. Cross-reactivity was 
70% to rat ANF 99-126, 13% to atriopeptin TI1 and 0.03% to 
atriopeptin I or 11. It  did not cross-react with a wide variety of 
peptides and proteins, including its immunization conjugate 
(bovine thyroglobulin). The final titer was 1:120,000 and the 
assay sensitivity was 0.5 fmole per assay tube. The 50% binding 
intercept of the standard curve was 10 fmol. One-ml plasma 
aliquots were extracted by adsorption to pre-rinsed Amberlite 
XAD-2 adsorbent resin (particle size: 0.3 to 1.0 mm; Serva, 
Heidelberg, Federal Republic of Germany). Recovery of syn- 
thetic human ANF 99-126 was approximately 67% in plasma 
of healthy subjects and 70% in plasma of cirrhotic patients. 
Validity of the radioimmunoassay for ANF determination in 
both normal and cirrhotic plasma was demonstrated by paral- 




(n= 11) (n = 10)  
Age (years) 61 f 2 56 f 3 
Sex (male/female) 813 812 
Child-Pugh score (A/B/C) 9 1 m  01614 
Bilirubin (mg/100 ml) 1.3 2 0.2 2.2 f 0.4 
Prothrombin time (%) 73 f 3 64 f 4 
Serum albumin (gm/100 ml) 4.1 f 0.2 3.7 + 0.2 
Mean arterial pressure (mmHg) 84.5 f 2.9 78.3 f 2.6 
Heart rate (beats/min) 74.2 f 2.3 82.8 f 2.8 
Serum creatinine (mg/100 ml) 1.0 2 0.1 1.2 2 0.1 
lelism of serial dilution curves with the standard curve and by 
the absence of significant binding interference. 
Clearance of creatinine as well as fractional sodium excretion 
(FeNa) were calculated by standard formulas. Mean arterial 
pressure was calculated as the sum of diastolic pressure and 
one-third of the difference between systolic and diastolic 
pressure. 
Data are given as mean and S.E. Random distribution of 
data was tested by the Kolmogorov-Smirnoff test. Statistical 
evaluation of randomly distributed data was performed by 
unpaired t test between groups and by paired t test within 
groups. Nonrandomly distributed data were analyzed by Mann- 
Whitney test between groups and by Wilcoxon test within 
groups. A p value of 0.05 or less was considered statistically 
significant. The Pearson correlation coefficient was determined 
by the usual linear least-squares method. 
RESULTS 
Atrial Natriuretic Factor. Basal ANF plasma 
concentrations of cirrhotic patients without ascites, cir- 
rhotic patients with ascites and controls were not signif- 
icantly different (Fig. 1). Volume stimulation by WI 
prompted a highly significant increase of ANF from 8.5 
f 1.3 fmoles per ml to 16.5 f 2.6 fmoles per ml (104 f 
16%) in patients without ascites, comparable to the 
stimulation from 6.0 f 0.6 fmoles per ml to 13.6 f 2.6 
fmoles per ml (117 f 29%) in controls. However, in 
patients with ascites, WI caused an increase from 7.7 k 
1.3 fmoles per ml to 11.4 f 2.3 fmoles per ml (46 f 18%) 
only. Thus, ANF stimulation by WI was significantly 
smaller in ascitic patients as compared to patients with- 
out ascites (p < 0.05). In the recovery period, ANF 
decreased toward baseline levels, although in cirrhotic 
patients with ascites no marked fall of stimulated values 
could be observed. 
Basal PRA was ele- 
vated in cirrhotic patients with ascites (28.9 9.4 ng 
angiotensin I (AI) per ml per hr) as compared to healthy 
subjects (5.3 f 0.9 ng A1 per ml per hr (Figure 2). PRA 
levels in cirrhotic patients without ascites were slightly 
higher than normal (8.6 f 2.8 ng A1 per ml per hr). WI 
reduced PRA rather uniformly to about one-half the 
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FIG. 1. ANF plasma concentrations in 25 healthy subjects, 11 cir- 
rhotic patients without ascites and 10 cirrhotic patients with ascites 
before, during and following head-out water immersion. * = p < 0.05, 
* *  = p < 0.01; * * *  = p < 0.001; significantly different from baseline 
values. 
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- ,Con t ro l s  Cbrrhot ics w i t h o u t  .Cirrhotics with ascites 
FIG. 2. Plasma renin activity in  healr h >  subjects. cirrhotic patients 
without and cirrhotic patients with ascites hefore. during and following 
water immersion. * *  = 11 < 0.01; +iificantly different lrom baseline 
values. 
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FIG. 3. Plasma aldosterone concentration in healthy subjects. cir- 
rhotic patients without and cirrhotic patients with ascites hefore. 
during and following water immersion. + = p < 0.05: * *  = p < 0.01; * * *  
= p < 0.001; significantlv different froni I 
17.3 & 6.9 ng A1 per ml per hr), patients without, ascit,es 
(by 43 & 10% to 4.8 f 1.8 ng A1 per ml per hr) and 
controls (by 46 & 8% to 2.4 k 0.3 ng A1 per ml per hr) .  
In the recovery period, PRA returned to preimmersion 
levels in controls and cirrhotic patients. 
PAC in cirrhotic patients with ascites was higher than 
in controls (63.9 + 19.9 ng per 100 ml vs. 13.0 * 1.7 ng 
per 100 ml), with levels of patients without ascites in 
between (38.1 f 11.3 ng per 100 ml) (Fig. 3) .  WI signifi- 
cantly reduced PAC in cont.rols (to 6.6 k 0.8 ng per 100 
ml) and in cirrhotic patients without ascites (t,o 26.6 t 
9.0 ng per 100 ml). The decrease in cirrhotic pat,ients 
with ascites (to 49.1 19.3 ng per 100 ml) did not quite 
reach significance (p = 0.07). When basal and immersion 
PRA values were plotted against the corresponding PAC 
values, significant correlations were seen in controls ( r  
= 0.56, p < 0.001) as well as in cirrhot.ic patients ( r  = 
0.53, p < 0.001). 
The effects of immersion on renal 
excretion are displayed in Table 2. Mean increases of 
Renal Response. 
TABI.E 2. Renal response to water immersion 
Cirrhotics 
('ontrols 
(n = 2 5 )  Without With ascites ascites 
(n = 1 1 )  (n = 10) 
I l r i n x y  voluine (ml/min)  
Basal 1.4 -t 0.2 1.n f 0.3 0.9 f 0.2 
Ini mersion 5.0 f 0.B' X 3  f 1.0'' 1.6 f 0.4' 
Kecovery 2.8 f 0.4'. 1 .6  f 0.5 1.1 f 0.6" 
1 'rinary sodium excretion 
I pnmles/niin I 
Basal 156 t 19 74 f 15' 28 f 11'' 
Inimersion 302 f 34' 149 k 50" 71 f 28' 
Recovery 182 f 28 102 f 35 22 f 7'" 
Basal 0.90 f 0.12 0.56 & 0.13 0.20 f 0.05"- 
1 mmersion 1.23 f 0.16' 0.94 f 0.29 0.35 f 0.10' 
Kecovery 1.23 f 0.17 '  0.89 C 0.24 0.20 f 0.05'" 
( 'reatinine clearance (ml/ 
inin I 
Basal Lr5B f 26 119 f 17 103 f 26 
Inimersion 96 f 31 
Recovery 117 & 15 72 f 14 63 k 13'' 
o = 11 < 0.05: h = p < 0.01; c = p < 0.001; significantly different from 
c i  = p < 0.05; c = p < 0.01; f = p < 0.001; significantly different from 
p = p < 0.05: significantly different from values in cirrhotic patients 
I)aseline values. 
corrcqwnding values in controls. 
without asciies. 
urinary volume were highly significant in healthy sub- 
jects (3.64 * 0.60 ml per min), still marked in cirrhotic 
patients without ascites (2.02 k 0.81 ml per min) but not 
significant (p  > 0.1) in cirrhotic patients with ascites 
(0.68 k 0.35 ml per min). Similar differences were ob- 
served in urinary sodium excretion: WI induced a rise by 
146 k 38 pmoles per min in healthy subjects, by 75 & 43 
pmoles per min in patients without and by 43 & 19 
pmoles per min in patients with ascites. Increases of 
natriuresis as well as of fractional sodium excretion 
missed the level of significance in cirrhotic patients 
without (UNaV: p = 0.13, FeNa: p = 0.10) as well as in 
cirrhotic patients with ascites (UNaV: p = 0.06, FeNa: p 
= 0.12). Creatinine clearance was not significantly al- 
tered in any group throughout the experiment (p > 0.1). 
Neither basal nor stimulated natriuresis or diuresis nor 
the degree of renal response correlated to the correspond- 
ing values of ANF, PRA or PAC. 
Relationship of Natriuresis with ANF and the 
Renin-Aldosterone System. The ratio of ANF over 
plasma aldosterone concentration (ANF/PAC) (Fig. 4) 
proved to be a useful marker of the apparent interaction 
of both systems. The ANF/PAC ratio increased from 
0.65 k 0.21 to  2.44 k 0.73 fmoles per lo-' ng in cirrhotic 
patients without ascites; this was not significantly dif- 
ferent from the stimulation in controls (0.63 f 0.11 to  
3.29 k 1.18 fmoles per lo-' ng). In cirrhotic patients with 
ascites, however, the elevation from 0.38 f 0.14 to 0.75 
k 0.24 fmoles per 10-' ng was significantly (p < 0.05) 
smaller than in cirrhotic patients without ascites or in 
controls. In cirrhosis, basal natriuresis (Fig. 5, r = 0.60, 
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FIG. 4. Ratio of ANF over plasma aldosterone concentration in 
healthy subjects, cirrhotic patients without and cirrhotic patients with 
ascites before, during and following water immersion. * = p < 0.05; * * *  
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Basal ANF Aldosterone ratio 
FIG. 5. Correlation of baseline sodium excretion to baseline ratio of 
ANF over plasma aldosterone concentration in patients with cirrhosis; 
r = 0.60, p < 0.01. Open squares = patients without ascites; closed 
squares = patients with ascites. 
p < 0.01) as well as basal fractional sodium excretion (r 
= 0.63, p < 0.01) correlated to the baseline ANF/PAC 
ratio. The ratio of stimulated ANF/PAC was related to 
stimulated natriuresis (r = 0.60, p < 0.01). In the 
subgroup of cirrhotic patients with ascites, the relation 
between basal natriuresis (r = 0.73, p < 0.02), stimulated 
natriuresis (Fig. 6) (r = 0.90, p < 0.001) as well as between 
the increase (r = 0.74, p < 0.02) of natriuresis and the 
corresponding ANF/PAC ratios was more clearly ex- 
pressed than in the subgroup without ascites. 
DISCUSSION 
In the present study, no significant difference of ANF 
plasma concentrations was observed between healthy 
subjects and patients with cirrhosis without and with 
ascites. Since substantial tissue extraction of ANF has 
been reported (25), similarity of venous plasma levels 
does not necessarily imply corresponding arterial plasma 
concentrations. However, it has recently been demon- 
strated (26) that arteriovenous extraction of ANF in 
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FIG. 6. Correlation of immersion-stimulated natriuresis to immer- 
sion-stimulated ratio of ANF over plasma aldosterone concentration 
in patients with cirrhosis and ascites; r = 0.90, p < 0.001. 
and that arterial ANF plasma concentrations in cirrhosis 
equal those in healthy subjects. 
The observation that acute volume stimulation by 
water immersion increases ANF plasma levels in healthy 
human subjects is in accordance with previous findings 
from our laboratory (27) and has been confirmed by 
several groups (28-31). Thus, immersion may be consid- 
ered a useful tool to study the reactivity of the ANF 
system in volume regulation, as has been shown for the 
renin-aldosterone system (21). Patients with cirrhosis of 
the liver without ascites exhibited increases of ANF 
plasma levels upon stimulation by water immersion sim- 
ilar to controls. In cirrhotic patients with ascites, how- 
ever, augmentation of plasma ANF after l hr of immer- 
sion was significantly blunted. Duration of immersion 
might have been too short to induce maximum ANF 
stimulation. Several 3-hr immersion studies reported 
mean maximum ANF stimulation within 1 hr immersion 
time (30-32), whereas Epstein et al., in a recently pub- 
lished investigation (29), observed individual peak ANF 
concentrations in eight of 13 healthy subjects only after 
2 or 3 hr immersion time. Since the same author observed 
slower and less marked effects of immersion on volume- 
regulating hormones and on sodium excretion in subjects 
on a low-sodium diet (33), a 150-mEq sodium diet was 
chosen for the present study, approximately the average 
sodium intake of a normal diet. Following our studies on 
ANF stimulation by WI in patients with cirrhosis (34, 
35), other investigators have submitted two (36) and 
eight cirrhotic subjects (37) to WI. In these studies, mean 
ANF plasma values reached a maximum after 1 hr im- 
mersion and remained elevated throughout the 3-hr im- 
mersion period. Thus, l-hr immersion appears sufficient 
to assess the ANF response to volume stimulation, al- 
though the possibility cannot be excluded that some 
subjects did not attain maximal ANF augmentation. 
Another explanation for the blunted ANF increase in 
cirrhotic patients with ascites might be a smaller degree 
of central volume stimulation in this subgroup of pa- 
tients. However, plasma renin activity as an indicator of 
centrally effective blood volume decreased in cirrhotic 
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patients with ascites by the same percentage as in cir- 
rhotic patients without ascites and in healthy subjects. 
The mean decrease of PRA by 50 k 6% in patients wit,h 
ascites in the present study compares well with the 45 _t 
7% decrease observed in 16 cirrhotic subjects after 1 hr 
WI in an earlier study by Epstein et al. (38). Besides, it 
has been shown that. intracardiac pressures are increased 
by immersion independent of the degree of ascites (39). 
Thus, although we cannot provide dat,a on central hemo- 
dynamics, a diminished increase of atrial pressure does 
not seem a likely explanation for t,he blunted ANF st.im- 
ulation in patients with ascites. Therefore, a defect, of' 
ANF release or a reduced cardiac ANF content may be 
suspected in cirrhotic patients with ascites. 
Preliminary observations of other investigators found 
a normal or even exaggerated ANF response to immer- 
sion (37) in cirrhotic patients with ascites on a sodium- 
restricted diet as compared to healthy subjects without 
sodium restriction. This discrepancy to our results can- 
not be easily explained. Possibly, differences in dietary 
sodium intake and presence of edema in these patients 
with ascites might account for the different observat.ions. 
Furthermore, in our patients with ascites, ANF plasma 
levels did not markedly decrease following the end of 
immersion, as  was the case in the group without. ascites 
and in the controls of our st,udy as well as in t,he cirrhotic 
patients of the aforementioned study (37). Despite per- 
sistent elevations of ANF plasma concentrations, natri- 
uresis returned to baseline levels in our patients with 
ascites. Although this observation might support the 
contention that renal sensitivity to ANF is blunted in 
cirrhotic patients with ascites (37,  40-44), stronger acti- 
vation of sodium-retaining syst,ems, not investigat,ed in 
the present study, cannot be excluded. 
So far, functional response of t.he renin-aldost,erone 
system to volume stimulation in various stages of cirrho- 
sis has not been well described. Whereas plasma renin 
activity was markedly elevated in ascitic patients, cir- 
rhotic patients without ascites showed similar baseline 
values as did healthy subjects. Water immersion reduced 
PRA to a similar degree in all groups, indicating a rat her 
uniform volume stimulus. Plasma aldosterone concentra. 
tion in cirrhotic patients with ascites was significantly 
higher than in controls, with levels of compensated cir- 
rhotic patients in between. Similar reduct.ions of PAC in 
controls and cirrhotics patient were seen, with the 
changes in the subgroup with ascit.es not quite reaching 
significance. In view of considerable disagreement in the 
literature on the role of the renin-aldosterone system in 
volume regulation of cirrhosis (45-471, the rather unan- 
imous activation of PRA and PAC, in our subgroup with 
ascites and in particular the trend t,o elevat.ed levels in 
the subgroup without ascites deserves attention. Possi- 
bly, the sitting position of the subjects in our study as 
compared to a supine posit,ion in many other studies 
might explain why we observed activat.ion of the renin- 
aldosterone system in cirrhosis which is not generally 
agreed upon (45). However, hormone levels in the sitting 
position may more closely reflect, the activity of the 
volume-regulating systems during about two-thirds of a 
regular day than concentrations taken in the supine 
position. Thus, our results underscore the importance of 
an activation of the renin-aldosterone system in volume 
regulation of patients with cirrhosis with and also with- 
out ascites. 
Neither ANF nor renin-aldosterone plasma levels were 
found to correlate to basal or stimulated natriuresis. In 
view of the complex interactions in volume regulation, 
this is not surprising; it seems likely that several hor- 
monal and neural factors act in concert and that several 
of them participate to induce sodium retention of cirrho- 
sis. ANF is the only well-characterized natriuretic hor- 
mone that can be reliably quantitat.ed as yet. ANF coun- 
teracts renin-aldosterone, the major sodium-retaining 
principle of cirrhosis, by inhibiting synthesis and release 
and by antagonizing the renal action. Therefore, the 
present study focussed on the possible role of ANF and 
renin-aldosterone in volume regulation of cirrhosis. 
Water immersion induced an increase of ANF and a 
decrease of plasma renin activity and plasma aldosterone 
concentration. In an attempt, to characterize the balance 
of these opposing systems, the ratio ANF over aldoster- 
one was calculated and correlated to the renal response. 
ANF/PAC was more markedly affected by immersion 
than ANF or PAC alone. In pat.ients with cirrhosis, but 
not in controls, basal as well as immersion-stimulated 
nat,riuresis was significantly correlated to the corre- 
sponding ANF/PAC ratios. The closer correlations in 
the subgroup with ascites might be due to the stronger 
aldosterone activation in basal conditions and the 
blunted ANF stimulation by immersion. Even though 
t,hese correlations do not necessarily imply a cause-effect 
relat.ionship, they might suggest a role of ANF, counter- 
acting aldosterone, in sodium handling. Thus, our results 
support the contention that these hormones are impor- 
t,ant for the volume regulation in patients with cirrhosis 
of the liver. 
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